Analystreport

Theravance Biopharma (TBPH) had its "neutral" rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.

Theravance Biopharma, Inc. - Ordinary Shares  (TBPH) 
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.theravance.com/investor-relations